Can an energy-deficient heart grow bigger and stronger?

Journal of the American College of Cardiology

Volumn 41, Issue 10, 2003, Pages 1783-1785

  Roberts, Robert ^a   Marian, Ali J ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CREATINE PHOSPHATE; MITOCHONDRIAL DNA; MYOSIN BINDING PROTEIN C; MYOSIN HEAVY CHAIN; TROPONIN T;

BIOENERGY; CALCIUM HOMEOSTASIS; ECHOCARDIOGRAPHY; GENE DELETION; GENE EXPRESSION; GENE MUTATION; HEART FAILURE; HEART HYPERTROPHY; HEART MUSCLE; HEART MUSCLE ISCHEMIA; HUMAN; MOLECULAR GENETICS; NOTE; PATHOGENESIS; PATHOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; SARCOMERE;

EID: 0037901412     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(02)03008-5     Document Type: Editorial

References (24)

1. Liouville H. Retrecessment cardiaque sous aortique. Gazette Med Paris 1869;24:161-5.
2. Marian AJ, Roberts R. The molecular genetic basis for hypertrophic cardiomyopathy. J Mol Cell Cardiol 2001;33:655-70.
3. Grossman W, Jones D, McLaurin LP. Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest 1975;56:56-64.
4. Nagueh SF, Kopelen HA, Lim DS, et al. Tissue Doppler imaging consistently detects myocardial contraction and relaxation abnormalities, irrespective of cardiac hypertrophy, in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 2000;102:1346-50.
5. Nagueh SF, Bachinski L, Meyer D, et al. Tissue Doppler imaging consistently detects myocardial abnormalities in patients with familial hypertrophic cardiomyopathy and provides a novel means for an early diagnosis prior to an independent of hypertrophy. Circulation 2001;104:128-30.
6. Ho CY, Sweitzer NK, McDonough B, et al. Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy. Circulation 2002;105:2992-7.
7. Geisterfer-Lowrance AA, Kass S, Tanigawa G, et al. A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation. Cell 1990;62:999-1006.
8. Phillips MF, Harper PS. Cardiac disease in myotonic dystrophy. Cardiovasc Res 1997;33:13-22.
9. Palau F. Friedreich's ataxia and frataxin: molecular genetics, evolution and pathogenesis. Int J Mol Med 2001;7:581-9.
10. Sachdev B, Elliott PM, McKenna WJ. Cardiovascular complications of neuromuscular disorders. Curr Treat Options Cardiovasc Med 2002;4:171-9.
11. Gollob MH, Green MS, Tang AS, et al. Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. N Engl J Med 2001;344:1823-31.
12. Blair E, Redwood C, Ashrafian H, et al. Mutations in the gamma(2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis. Hum Mol Genet 2001;10:1215-20.
13. Arad M, Benson DW, Perez-Atayde AR, et al. Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. J Clin Invest 2002;109:357-62.
14. Marian AJ, Roberts R. Molecular pathogenesis of cardiomyopathies. In: Sperelakis N, Kurachi Y, Terzic A, Cohen M, editors. Heart Physiology and Pathophysiology. San Diego, CA: Academic Press, 2000:1045-63.
15. Marian AJ. Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy. Lancet 2000;355:58-60.
16. Marian AJ. Modifier genes for hypertrophic cardiomyopathy. Curr Opin Cardiol 2002;17:242-52.
17. Crilley JG, Boehm EA, Blair E, et al. Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J Am Coll Cardiol 2003;41:1776-82.
18. 31 P NMR spectroscopy detects metabolic abnormalities in asymptomatic patients with hypertrophic cardiomyopathy. Circulation 1998;97:2536-42.
19. 31 P NMR spectroscopy reveals decreased PCr/Pi in patients with severe hypertrophic cardiomyopathy. Am J Cardiol 1997;80:34A-40A.
20. 31 P nuclear magnetic resonance spectroscopy: a noninvasive tool to monitor metabolic abnormalities in left ventricular hypertrophy in human. Am J Cardiol 1999;83:19H-24H.
21. 31 P MR spectroscopy in hypertrophic cardiomyopathy: comparison with T1-201 myocardial perfusion imaging. Am Heart J 1993;125:1323-8.
22. Crilley JG, Boehm EA, Rajagopalan B, et al. Magnetic resonance spectroscopy evidence of abnormal cardiac energetics in Xp21 muscular dystrophy. J Am Coll Cardiol 2000;36:1953-8.
23. Zhang J. Myocardial energetics in cardiac hypertrophy. Clin Exp Pharmacol Physiol 2002;29:351-9.
24. Weiss RG, Chatham JC, Georgakopolous D, et al. An increase in the myocardial PCr/ATP ratio in GLUT4 null mice. FASEB J 2002;16:613-5.